Rheumatic Fever

1. Front Matter

   Pages i-x

   PDF

2. Definitions, History, and Geography

   • Angelo Taranta, Milton Markowitz

   Pages 1-9

3. Etiology and epidemiology

   • Angelo Taranta, Milton Markowitz

   Pages 10-18

4. Pathogenesis and pathology

   • Angelo Taranta, Milton Markowitz

   Pages 19-29

5. Clinical manifestations

   • Angelo Taranta, Milton Markowitz

   Pages 30-43

6. Laboratory manifestations

   • Angelo Taranta, Milton Markowitz

   Pages 44-47

7. Diagnosis

   • Angelo Taranta, Milton Markowitz

   Pages 48-52

8. Differential diagnosis

   • Angelo Taranta, Milton Markowitz

   Pages 53-60

9. Treatment

   • Angelo Taranta, Milton Markowitz

   Pages 61-65

10. Sequels of rheumatic fever: chronic rheumatic heart disease

    • Angelo Taranta, Milton Markowitz

    Pages 66-70

11. Rheumatic recurrences

    • Angelo Taranta, Milton Markowitz

    Pages 71-74

12. Prevention of recurrent attacks

    • Angelo Taranta, Milton Markowitz

    Pages 75-83

13. Prevention of first attacks of rheumatic fever

    • Angelo Taranta, Milton Markowitz

    Pages 84-89

14. Role of health care workers other than physicians in the control of rheumatic fever

    • Angelo Taranta, Milton Markowitz

    Pages 89-92

15. The future of rheumatic fever

    • Angelo Taranta, Milton Markowitz

    Pages 93-95

16. Back Matter

    Pages 96-99

    PDF

Today rheumatic fever is still the most common cause of heart disease in children and young adults in developing countries. This disease is typically associated with poverty, in particular with poor housing, overcrowding and inadequate medical care. Rheumatic fever has almost disappeared from economically developed countries; this trend has paralleled improvements in standards of living. However, the recent resurgence of rheumatic fever in middle-class families in the U. S. A. has re-emphasized the importance of this disease in the developed countries as well. Prevention and control of rheumatic fever and rheumatic heart disease is an important part of the WHO cardiovascular disease program. Based on earlier WHO experience, and on the magnitude of the problem, it was realized that concerted action was needed to combat this significant cause of cardiovascular morbidity and mortality. The present program has been developed on the principle that sound knowledge and reliable technology already exist for implementing community programs for the prevention and control of rheumatic fever and rheumatic heart disease with the intention of extending activities toward nationwide coverage. The first edition of this book was an excellent instrument to assist in the control of this disease. The present volume with dissemination of knowledge to health personnel will contribute to closing the gap between knowledge and implementation and it links with WHO's endeavors in prevention and control of rheumatic fever and rheumatic heart disease.

• antimicrobial
• infection
• infections
• pathogenesis
• vaccine
• infectious diseases

• New York Medical College, New York City, USA

  Angelo Taranta

• Cabrini Medical Center, New York City, USA

  Angelo Taranta

• University of Connecticut School of Medicine, Farmington, USA

  Milton Markowitz

Policies and ethics